Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Z Qian

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
The Prostate|October 30, 2009
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicityDavid Z Qian, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2007
Platelets take up the monoclonal antibody bevacizumabHenk M W Verheul, Martijn P J Lolkema, David Z Qian, et al.
Cancer Research|April 15, 2010
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21Hao Geng, Brooks L Rademacher, Janet Pittsenbarger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Prostate cancer-associated gene expression alterations determined from needle biopsiesDavid Z Qian, Chung-Ying Huang, Catherine A O'Brien, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 21, 2008
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growthHuafeng Zhang, David Z Qian, Yee Sun Tan, et al.
Nature Biotechnology|November 12, 2021
Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing dataDuanchen Sun, Xiangnan Guan, Amy E Moran, et al.
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
The Prostate|October 30, 2009
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicityDavid Z Qian, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2007
Platelets take up the monoclonal antibody bevacizumabHenk M W Verheul, Martijn P J Lolkema, David Z Qian, et al.
Cancer Research|April 15, 2010
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21Hao Geng, Brooks L Rademacher, Janet Pittsenbarger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
Prostate cancer-associated gene expression alterations determined from needle biopsiesDavid Z Qian, Chung-Ying Huang, Catherine A O'Brien, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 21, 2008
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growthHuafeng Zhang, David Z Qian, Yee Sun Tan, et al.
Nature Biotechnology|November 12, 2021
Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing dataDuanchen Sun, Xiangnan Guan, Amy E Moran, et al.
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Pageof 5